Clinical Trials Browser

Completed × Neoplasms × lirilumab × Clear all

NCT01714739 2023-02-02

A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors

Phase 1/2 Completed

337 enrolled 42 charts

Neoplasms

NCT01750580 2015-07-22

Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor

Phase 1 Completed

Neoplasms